Open Menu icon
JOIN
SEARCH
Home
Blog

Biosimilars Council Press Releases

Blog
  • Blog

Reinventing AAM’s Meetings
  • Blog

FDA Approvals: Good News for Patients, More Work to Do (Part 2)
  • Blog

The Biosimilars Council Congressional Briefing: Five Takeaways
  • Blog

AAM Has Adopted a Code of Business Ethics. Here’s What That Means.
  • Blog

AAM Speaks on Involvement in the Prescription Drug Safety Network
  • Blog

Gold and Platinum Hermes Awards for AAM
  • Blog

Access! 2017 Recap: Ramping Up for AAM’s 2018 Annual Meeting
  • Blog

AAM’s Comments on USTR’s Proposed China Tariffs
  • Blog

Dear Mr. President—On the Eve of Your Drug-Pricing Speech
  • Blog

FDA Approvals: Good News for Patients, More Work to Do (Part 1)
  • Blog

Recap of Access! 2018 — Delivering on the Promise of Generics and Biosimilars (Part 3)
  • Blog

Recap of Access! 2018 — Chip’s Call to Action (Part 2)
Load More
JOIN
SEARCH